Dr. Reddy’s Secures Brazil Approval for Generic Semaglutide Injection
Dr Reddys Laboratories Ltd · Press Release · 05 Nov 2026, 3:17 pm
Dr. Reddy’s Secures Brazil Approval for Generic Semaglutide Injection Dr. Reddy’s Laboratories received marketing authorization from Brazil’s ANVISA on 5th Nov'26 for generic semaglutide injection to treat type 2 diabetes. The product will launch in Brazil via a partnership with Aché as a once-weekly pre-filled pen across two presentations (2 mg/1.5 mL and 4 mg/3 mL). The authorization expands the company's footprint in Brazil, where the semaglutide market for diabetes is estimated at approximately USD 244.6 million (IQVIA, MAT Sep'26), addressing a patient base of 16.6 million adults.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
- Audio Recording of the Earnings call conducted on October 23, 2026 · 24 Oct 2026
